Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Juncti
Go back to Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Juncti| (NASDAQ: CELU) | Delayed: 0.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.73 | 52 Week High | $ | |||
| Open | $0.73 | 52 Week Low | $ | |||
| Day High | $0.73 | P/E | N/A | |||
| Day Low | $0.73 | EPS | $ | |||
| Volume | 415 | |||||
